无锡诺宇医药科技

Nuoyu Pharma is a clinical-stage biotechnology company based in Wuxi, China, specializing in the development of innovative radiopharmaceuticals. The company focuses on Radionuclide Drug Conjugates (RDCs) for the diagnosis and treatment of various cancers, including prostate and pancreatic cancer. Utilizing its proprietary mSca (mini-Scaffold) technology platform, Nuoyu Pharma designs high-affinity molecules with optimized pharmacokinetics for targeted radiation delivery. Its lead programs include NYM032, targeting PSMA, and NYM005, targeting FAP. The company aims to provide integrated theranostic solutions to address unmet medical needs in oncology. Nuoyu Pharma maintains a robust pipeline of diagnostic and therapeutic candidates designed to improve patient outcomes through precision medicine.